We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Waters Introduces new UPLC Solution for Glycan Characterization
Product News

Waters Introduces new UPLC Solution for Glycan Characterization

Waters Introduces new UPLC Solution for Glycan Characterization
Product News

Waters Introduces new UPLC Solution for Glycan Characterization


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Waters Introduces new UPLC Solution for Glycan Characterization"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Waters Corporation introduced the first UltraPerformance LC® (UPLC®) analytical solution for the characterization of 2-AB labeled glycans from glycoproteins. The UPLC solution combines new ACQUITY® UPLC BEH Glycan Columns with the ACQUITY UPLC System equipped with fluorescence detection.

Current FDA regulations require that firms developing and manufacturing therapeutic proteins are able to characterize the glycans attached to those proteins to ensure the efficacy and safety of a biopharmaceutical product.

Waters is introducing this solution at the request of scientists seeking to apply the power of UPLC technology to the development and analysis of glycans derived from therapeutic proteins.

“Customers were looking for improvements in LC resolution that would lead to more confident glycan identification and quantitation” said Mark Baynham, Director of Marketing, Chemistry Operations, Waters Division.

“With the introduction of our new UPLC BEH Glycan columns and ACQUITY UPLC Technology we have also responded to the increased pressure on their organizations for high throughput by providing UPLC benefits such as shortened analysis times without compromising their desired resolution.”

Initial customer feedback has shown the UPLC solution to be up to three times faster than traditional HPLC for the analysis of 2-aminobenzamide (2AB)-labeled glycans from human IgG.

In addition, to ensure confidence in long-term use in customer validated methods all ACQUITY UPLC BEH Glycan columns will be quality-control tested with relevant labeled glycan standards for consistent batch-to-batch column performance.

Expanding the Capabilities of UPLC Technology Waters ACQUITY UPLC BEH Glycan columns provide superior resolution for a wide range of glycans and represent the fifth application-tested UPLC column and eleventh UPLC chemistry added to the ever-expanding ACQUITY UPLC column family.

ACQUITY UPLC BEH Glycan columns are produced with the Waters Designed for Six Sigma (DFSS) Phase II ACQUITY UPLC column manufacturing process. This process produces long term performance by maximizing efficiency while minimizing column-to-column variability.
Advertisement